Saturday - December 27, 2025
Breakthrough T1D Applauds Launch of Lilly's Phase 3 Clinical Trials
October 30, 2025
NEW YORK, Oct. 30 -- Breakthrough T1D (formerly JDRF) a non-profit dedicated to funding type 1 diabetes research, posted the following news release:

* * *

Breakthrough T1D Applauds Launch of Lilly's Phase 3 Clinical Trials

*

Breakthrough T1D is encouraged by Eli Lilly and Company's announcement of two new phase 3 clinical trials for baricitinib in type 1 diabetes (T1D). The BARICADE-DELAY and BARICADE-PRESERVE studies will further inv . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products